

RIGEL PHARMACEUTICALS INC

Form 8-K

February 03, 2004

## SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

### FORM 8-K

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of Report (date of earliest event reported): **February 3, 2004**

Date of Filing: **February 3, 2004**

## RIGEL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

**Delaware**  
(State of jurisdiction)

**0-29889**  
(Commission File No.)

**94-3248524**  
(IRS Employer Identification No.)

**1180 Veterans Boulevard, South San Francisco, CA 94080**

(Address of principal executive offices and zip code)

**(650) 624-1100**

Registrant's telephone number, including area code:



**Item 12. Results of Operations and Financial Condition**

On February 3, 2004, Rigel Pharmaceuticals, Inc. issued a press release announcing financial results for the three months ended December 31, 2003, as well as for the year ended December 31, 2003. A copy of such press release, entitled "Rigel Announces Fourth Quarter and Year End 2003 Financial Results," is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

The information in this Report on Form 8-K, including the exhibit hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the United States Securities and Exchange Commission made by Rigel Pharmaceuticals, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**Rigel Pharmaceuticals, Inc.**

Dated: February 3, 2004

By: */s/ James H. Welch*  
James H. Welch  
*Vice President, Chief Financial Officer and Secretary*

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press release entitled Rigel Announces Fourth Quarter and Year End 2003 Financial Results, dated February 3, 2004.